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Abstract
Therapeutic hypothermia has become an accepted part of post-resuscitation care. Efforts to shorten
the time from return of spontaneous circulation to target temperature have led to the exploration of
different cooling techniques. Convective-immersion uses a continuous shower of 2°C water to
rapidly induce hypothermia. The primary purpose of this multi-center trial was to evaluate the
feasibility and speed of convective-immersion cooling in the clinical environment. The secondary
goal was to examine the impact of rapid hypothermia induction on patient outcome.
24 post-cardiac arrest patients from 3 centers were enrolled in the study; 22 agreed to participate
until the 6-month evaluations were completed. The median rate of cooling was 3.0°C/h. Cooling
times were shorter than reported in previous studies. The median time to cool the patients to target
temperature (<34°C) was 37 min (range 14–81 min); and only 27 min in a subset of patients
sedated with propofol. Survival was excellent, with 68% surviving to 6 months; 87% of survivors
were living independently at 6 months.
☆A Spanish translated version of the abstract of this article appears as Appendix in the final online version at doi:10.1016/
j.resuscitation.2009.12.025.
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Conductive-immersion surface cooling using the ThermoSuit® System is a rapid, effective method
of inducing therapeutic hypothermia. Although the study was not designed to demonstrate impact
on outcomes, survival and neurologic function were superior to those previously reported,
suggesting comparative studies should be undertaken. Shortening the delay from return of
spontaneous circulation to hypothermic target temperature may significantly improve survival and
neurologic outcome and warrants further study.
Keywords
Hypothermia; Cardiac arrest
1. Introduction
Mild therapeutic hypothermia reduces mortality and morbidity after cardiac arrest. Two
large multi-center randomized controlled trials1,2 have shown that reducing a patient's core
temperature to a target range of 32–34°C following resuscitation from cardiac arrest can
improve important intermediate and long-term outcomes compared to supportive therapy
without cooling. A third trial showed improvements in metabolic endpoints for patients who
present with pulseless electrical activity or asystole. Experimental studies3–13 suggest that
the period of therapeutic hypothermia reduces neuronal damage by minimizing oxygen
consumption, reducing inflammation and edema, and possibly by stimulating the release of
protective proteins.
The clinical benefits of therapeutic hypothermia are thought to be greatest when
administered early after return of spontaneous circulation. The 2005 AHA/ILCOR
Guidelines14 recommend that therapeutic hypothermia be considered early after a cardiac
arrest (class 2). The European Council on Resuscitation recommends that “cooling should be
started as soon as possible”15 and the Canadian Association of Emergency Physicians
recommends that for selected patients “cooling should begin as soon as the clinical situation
allows.”16,17
The challenge of cooling patients rapidly is a difficult one. Commonly employed cooling
methods include cold saline infusion, ice-packs, and fan-and-misting techniques. There are a
variety of approved devices available that offer both whole body and partial body cooling
using external or intravascular methods, all developed in an effort to speed and simplify the
cooling process.15 The interval from the return of spontaneous circulation (ROSC) to
achieving target temperatures of therapeutic hypothermia is highly variable. If cooling
strategies require complex or invasive equipment, require transfer to higher levels of care, or
if they incur delays because of slow cooling rates, the therapeutic benefit achieved may be
suboptimal.16
Ice water immersion has previously been demonstrated to produce very rapid cooling in
humans,18,19 particularly when the water is circulating and providing an additional
convective heat loss. We refer to this method of hypothermia induction as convective-
immersion surface cooling. The ThermoSuit® System (TSS) (Life Recovery Systems) is a
whole body cooling device which has been described previously.20 It uses convective-
immersion by circulating ice water from a perforated top-sheet and an under-blanket across
the skin surface at a rapid rate (14 L/min).
The primary purpose of this trial was to observe the feasibility and speed of cooling of the
ThermoSuit® System in the clinical environment. The secondary goal was to examine the
impact of rapid hypothermia induction on patient outcome.
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2. Methods
This was a multi-center observational study. Patients were recruited from the Vienna
General Hospital, Vienna, Austria; St. Michael's Hospital, Toronto, Canada; and Kingston
General Hospital, Kingston, Canada. The study protocol received ethical approval from each
institutional review board. Study monitoring and database management was performed by i3
Innovus (Burlington Ontario, Canada).
We included patients who had a cardiac arrest of presumed cardiac origin who were
successfully resuscitated to a spontaneous rhythm but had persistent neurological
dysfunction (Glasgow Coma Score<8). We excluded patients with an estimated or known
age<18 years, patients who could not have an oesophageal temperature probe successfully
inserted, patients for whom the resuscitation lasted longer than 60 min, patients with a core
temperature less than 35°C after return of spontaneous circulation (ROSC), patients with a
comatose state prior to the cardiac arrest, pregnant patients, patients with a known terminal
illness, patients with known enrollment in another study, patients requiring urgent surgery,
patients with a coagulopathy and active bleeding, patients more than 4 h after ROSC and
patients with haemodynamic instability (SBP < 90 mmHg or MAP < 60 mmHg for >30 min
after ROSC despite vasopressors). Patients with a height greater than 188 cm or elbow-to-
elbow length greater than 60 cm were excluded due to size limitations of the cooling device.
Study patients meeting inclusion/exclusion criteria were placed in the device (Fig. 1) in
accordance with the product's instructions for use (Life Recovery Systems, Waldwick, NJ,
USA). In accordance with the local ethics committee requirements and regulations a waiver
of consent was used to prevent delays in patient care, with confirmation of consent for use of
study data from the patient or patient's substitute decision-maker when they became
available. Sedation, analgesia, and paralysis (if used) were administered prior to the start of
cooling according to standard institutional procedure for post-resuscitative therapeutic
hypothermia. Medications and their dosages were recorded from the medical record.
Adhesive defibrillation pads were applied to the patient in the conventional locations and an
esophageal temperature probe was inserted for continuous temperature monitoring. Wounds,
catheterization sites and defibrillation electrodes were covered with occlusive dressings
prior to activating the device. Defibrillation was provided if required without
discontinuation of the cooling process.
Cooling was initiated by circulating ice-cold water (2.0 ± 2.0°C) through the TSS. The
clinician was prompted to purge the fluid from the suit when the patient's oesophageal
temperature reached 34.5°C. This was intended to produce a final patient oesophageal
temperature of 32–34°C, which we used to define our target temperature. Cooling time was
defined as time from activation of water flow over the patient to core temperature reaching
the target range.
Patients were removed from the device and maintained at 32–34°C using warming or
cooling techniques at the discretion of the treating physician for 12–24 h. The patients were
then re-warmed at a target rate of 0.2–0.5°C/h using passive blankets or a conventional
heating blanket.
Patient data collected included time of start of cooling, time of purging of the TSS,
temperature of water infused through the suit, oesophageal temperature, blood pressure,
heart rate and rhythm, and electrocardiogram (ECG). Episodes of shivering and drugs
administered to control shivering or discomfort were recorded.
The primary outcome measure was time from collapse to a core temperature of 34.0°C.
Other data collected included cardiac arrest time, drug administration, operator interaction
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with the device, and adverse events. Safety parameters measured included survival at 24 h,
hospital discharge, 30 days, and 6 months. Mini-Mental Status Exam (MMSE), Modified
Rankin Score (MRS) and Cerebral Performance Category (CPC) were collected 30 ± 7 days
and 6 months ± 15 days post-event. MMSE was also collected at hospital discharge ± 3
days. Information was collected at 6 months regarding whether the surviving patients were
living independently or required long-term care.
3. Results
A total of 24 patients with post-resuscitative coma were enrolled. Two patients were
excluded after declining to give consent for neurological assessments. Table 1 shows the
characteristics of the patients enrolled, while Table 2 shows the cooling time and rate,
survival, and neurologic outcomes.
The median time from initiation of cooling to the target core temperature (34°C) was 37
min. 87% of the patients reached target temperature in less than 60 min, and 33% reaching
target in 30 min or less. A subgroup of patients who received propofol as their sedating
agent had a significantly shorter cooling time. The median rate of cooling for all patients
was 3°C/h, with the propofol group achieving a median rate of 4.2°C/h. Fig. 2 demonstrates
the mean esophageal temperature change in the first 30 min of cooling.
There were no serious adverse patient events related to the device. There was one reported
device malfunction that did not alter the care of the patient. Thirteen patients had core
temperatures that dropped below 32°C, and the median time spent below 32°C was 180 min
(75% quartile 317 min). There was no association between the minimum patient temperature
and patient outcome in this study.
Only five of the study patients required additional cooling to maintain them in the
therapeutic range for the entire 24 h of therapy, the remaining 17 patients remained in the
target core temperature range passively.
Of the 22 patients who consented to follow-up, 68% survived to 6 months. 87% of these
survivors were living independently. Time from ROSC to target temperature was
significantly lower in survivors than non-survivors (Table 3).
4. Discussion
Convective-immersion cooling resulted in significantly shorter cooling times than
previously reported. There was no control group in this study using an alternative cooling
device, but this method appears to be much better than those reported in previous trials. The
cooling rate of 3.0°C/h achieved with the device compares quite favorably to the rate of 0.9
°C/h reported in the Bernard trial.2 In the HACA trial,1 which used a combination of
methods, had a median time to target temperature of 480 min, while the Bernard trial2
achieved 120 min—still more than three times the 37 min achieved with conductive-
immersion using the ThermoSuit® System.
In 2007 Hoedemaekers et al. published a prospective comparison of methods of hypothermia
induction (Table 4). The most rapid cooling rate they achieved was with an intravascular
cooling device at 1.46°C/h, half the rate achieved by the ThermoSuit.20
Skin surface cooling using water slightly above the freezing point produces mild cutaneous
vasodilatation. This phenomenon has been described as the “Lewis Reaction” or “hunting
effect”, a reversal of the normal vasoconstrictive response to cold in part due to reduced
contractility of the walls of the arterioles at temperatures below 8°C.21–23 This enhances the
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rate of heat transfer through the skin and accelerates core cooling. Use of propofol as a
sedating agent seemed to shorten cooling times further, possibly due to the vasodilatory
effect of the drug.
Although the study is too small to make conclusions about outcome, there is an apparent
correlation between shorter time to target temperature and survival on subgroup analysis
within the study (Table 3). Wolff et al.24 had a similar finding when they studied 49 patients
cooled with intravascular catheters and concluded that a 1-h delay in reaching target
temperature tended to worsen the likelihood of a favorable outcome by 31%. Direct
evidence of survival benefit from more rapid induction of therapeutic hypothermia in a
controlled human study may no longer possible due to a loss of clinical equipoise but the
results of this study support the commonly held belief that the sooner therapeutic
hypothermia is achieved, the better the patient's neurologic outcome.
Time from ROSC to target temperature involves a number of system issues in addition to the
effectiveness of the cooling methods. Stabilization of the patient, interfacility and
interdepartmental transfers can significantly delay the initiation of cooling and the time to
target temperature. As more rapid cooling methods are developed, these delays will
comprise a greater proportion of the overall time interval. As we move the time it takes to
cool patients from 8 h toward 30 min, a 1-h delay in cooling initiation becomes much more
significant. Issues of who will initiate cooling and where it will be initiated may need to be
reexamined in some systems.
The high survival rates achieved in this study were accompanied by a high percentage of
patients living independently at 6 months. Although survival is often considered the ultimate
outcome measure, consideration of quality of life will continue to be of concern to clinicians
and patients alike. In addition to objective, numeric neurologic assessments like the MMSE,
MRS and CPC, the ability to live independently is a very meaningful measure that should
continue to be a part of the long-term evaluation of these interventions.
Once the patients were cooled to the target temperature they tended to remain in the target
range when left exposed to room air. Only 5 of the study patients required any additional
cooling to maintain them in the therapeutic range for the entire 24 h of therapy. Those that
did require temperature maintenance could be maintained at the desired level with simple
means such as conventional cooling blankets or temperature-controlled air. This is in
contrast to studies that used the application of cold fluids, where most of the patients re-
warmed spontaneously and needed additional cooling.25 This might be explained by the
higher heat mass that can be removed by conductive-immersion cooling.
The study has a number of limitations. As a feasibility study, there was not a comparison
group using another method of cooling. Comparison to historical controls is always difficult
due to variations in patient populations and other treatment provided. The study is too small
to make conclusions about outcomes, although the results are hypothesis generating.
This study was designed primarily to assess the feasibility of cooling with the ThermoSuit
and secondarily to assess outcomes. Convective-immersion surface cooling by the
ThermoSuit was rapid and effective. The measured outcomes are among the best reported,
despite the inclusion of patients who presented with pulseless electrical activity and asystole.
Further efforts to shorten the time from ROSC to therapeutic hypothermia, and further study
of the impact of this simple, effective cooling method are essential.
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5. Conclusion
Conductive-immersion surface cooling using the ThermoSuit® System is a rapid, effective
method of inducing therapeutic hypothermia. Although the study was not designed to
demonstrate impact on outcomes, survival and neurologic function were superior to those
previously reported, suggesting comparative studies should be undertaken. Shortening the
delay from return of spontaneous circulation to hypothermic target temperature may
significantly improve survival and neurologic outcome and warrants further study.
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Fig. 1.
The Life Recovery Systems ThermoSuit® System, which uses convective-immersion to cool
patients.
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Fig. 2.
Mean esophageal temperature with standard deviations for the first 30 min of cooling.
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Table 1
Patient characteristics.
Height 175(172–180) cma
Age 65(50–80) years
Presenting rhythm
 VF/VT 14/22(63.6%)
 PEA 7/22(31.8%)
 Asystole 1/22(4.5%)
Duration of resuscitation 18.0(15.3–25.0) mina
Starting temperature 36.1(35.5–6.8) °Ca
a
Median (interquartile range).
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Table 2
Outcomes.
Cooling time (min) All patients (n: 22) Sedated with propofol (n: 7) Sedated with other agents (n: 15)
Minimum 14.0 14.0 21.0
Maximum 81.0 39.0 81.0
Median (interquartile range) 37.0(27.25–48.75) 27.0(22.5–32.5) 46.0(31.0–57.5)
Mean (std. dev.) 40.0(17.3) 27.1(8.4) 45.9(17.0)
Cooling rate (°C/h)
Minimum 1.3 2.5 1.3
Maximum 8.8 8.8 7.9
Median (interquartile range) 3.0(2.3–3.9) 4.2(2.9–5.9) 2.7(2.0–3.5)
Mean (std. dev.) 3.5(2.0) 4.7(2.5) 3.0(1.6)
Patient outcomes (n: 22)
Survival to 6 months 15(68.1%)
Living independently 13(59.1%)
Neurologic testing (at 6 months) CPC MMSE MRS
Median (interquartile range) 1(1–1) 28(28–29) 0(0–1)
Mean (std. dev.) 1.23(.60) 27.9(2.23) 0.61(1.12)
Std. dev.: standard deviation; CPC: Cerebral Performance Category; MMSE: Mini-Mental Status Exam; MRS: Modified Rankin Score.
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Table 3
Survival and time to 34°C.
Time from ROSC to 34°Ca (min) All patients (22) Survivors (15) Non-survivors (7)
Minimum 109 109 114
Maximum 422 348 422
Median (interquartile range) 204(145–246) 184(145–234) 220(155–256)
Mean (standard deviation) 210(85) 196(73) 232(101)
ROSC: return of spontaneous circulation.
a
Time interval includes time to stabilize patient, transfer to definitive care, set-up and induction of therapeutic hypothermia.
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Table 4
Comparison of available cooling methods.
Cooling method Rate of cooling (°C/h)
ThermoSuit with propofol sedation 4.2a
EmcoolPads 3.3b
ThermoSuit 3.0a
Intravascular catheter 1.46c
Water-circulating blanket 1.33c
Gel-coated external device 1.04c
Conventional (cold saline and ice-packs) 0.32c
Air-circulating device 0.18c
a
Median rate of cooling, from this trail.
b
Median rate of cooling, data from Uray et al.26
c
Mean cooling, data from Hoedemaekers et al.20
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